OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Paulson Discusses the Current Treatment for NETs

September 5th 2018

Scott Paulson, MD, co-director of the Gastrointestinal Research Program for The US Oncology Network, medical director for the Neuroendocrine Research and Treatment Center at Baylor Charles A. Sammons Cancer Center, Baylor University Medical Center, discusses the current treatment of patients with neuroendocrine tumors.

Dr. Baz on Selinexor in Multiple Myeloma

September 5th 2018

Rachid Baz, MD, associate member, head of the Myeloma Section at Moffitt Cancer Center, discusses the potential use of selinexor (KPT-330) in patients with multiple myeloma.

Dr. Goy on Immunotherapy in Mantle Cell Lymphoma

September 5th 2018

Andre Goy, MD, MS, chief, Division of Lymphoma, chairman and director, John Theurer Cancer Center, discusses the potential of immunotherapy in patients with mantle cell lymphoma (MCL).

Dr. Arun on Immunogenicity in Triple-Negative Breast Cancer

September 5th 2018

Banu Arun, MD, professor in the Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses immunogenicity in triple-negative breast cancer (TNBC).

Dr. Herzog on Impact of Recent Clinical Trials in Ovarian Cancer

September 4th 2018

Thomas Herzog, MD, professor of obstetrics and gynecology, deputy director, University of Cincinnati Cancer Institute, discusses the impact of recent clinical trials in ovarian cancer.

Dr. Agarwala on Entinostat for Patients with Melanoma Who Progress on PD-1/PD-L1 Blockade

September 4th 2018

Sanjiv S. Agarwala, MD, chief of medical oncology and hematology, St. Luke’s Cancer Center, professor of medicine, Temple University School of Medicine, discusses the impact of entinostat for patients with melanoma who progress on a PD-1/PD-L1 blocking antibody.

Dr. Flaherty on the Tolerability of Encorafenib/Binimetinib in Melanoma

August 31st 2018

Keith T. Flaherty, MD, director, Termeer Center for Targeted Therapy, Massachusetts General Hospital Cancer Center, professor of medicine, Harvard Medical School, discusses the tolerability of the combination of encorafenib (Braftovi) and binimetinib (Mektovi) in patients with melanoma.

Dr. Shain Discusses Novel Agents in Multiple Myeloma

August 31st 2018

Kenneth H. Shain, MD, PhD, assistant member, Moffitt Cancer Center, discusses novel agents in multiple myeloma.

Dr. Sweet Discusses TKI Discontinuation in CML

August 31st 2018

Kendra Sweet, MD, an assistant member in the Department of Malignant Hematology at Moffitt Cancer Center, discusses discontinuation of tyrosine kinase inhibitor (TKI) therapy in chronic myeloid leukemia.

Dr. Kuykendall on the Impact of Ruxolitinib in Myeloproliferative Neoplasms

August 31st 2018

Andrew T. Kuykendall, MD, assistant member, Moffitt Cancer Center, discusses the impact of ruxolitinib (Jakafi) in myeloproliferative neoplasms (MPNs).

Dr. Reardon on Efficacy/Safety of Immunotherapy Combination in Glioblastoma

August 31st 2018

David A. Reardon, MD, clinical director, Center for Neuro-Oncology, Dana-Farber Cancer Institute, discusses the safety and efficacy data of an immunotherapy combination in glioblastoma.

Dr. Naidoo on Treating Immune-Related Adverse Events in NSCLC

August 31st 2018

Jarushka Naidoo, MBBCh, assistant professor of oncology, Johns Hopkins University, discusses the treatment of patients with non–small cell lung cancer who develop immune-related adverse events (irAEs).

Dr. Coleman on Classifying Patients With Ovarian Cancer

August 31st 2018

Robert Coleman, MD, professor in the department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, discusses the classification of patients with ovarian cancer.

Dr. Singal on Emerging Systemic Therapies in HCC

August 31st 2018

Amit G. Singal, MD, associate professor, UT Southwestern Medical Center, discusses emerging systemic therapies in hepatocellular carcinoma.

Dr. Tolaney Discusses Unmet Needs in ER+ Breast Cancer

August 31st 2018

Sara M. Tolaney, MD, MPH, instructor of medicine, Harvard Medical School, attending physician of medical oncology, Dana-Farber Cancer Institute, discusses unmet needs in the treatment of patients with estrogen receptor (ER)-positive breast cancer.

Dr. Choy Discusses Therapy for Oligometastatic Lung Cancer

August 31st 2018

Hak Choy, MD, Nancy B. & Jake L. Hamon Distinguished Chair in Therapeutic Oncology Research, Department of Radiation Oncology, UT Southwestern Medical Center, discuses therapy for patients with oligometastatic lung cancer.

Dr. Siefker-Radtke on Next Steps With Erdafitinib in Bladder Cancer

August 31st 2018

Arlene O. Siefker-Radtke, MD, professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses next steps with erdafitinib in patients with bladder cancer.

Dr. Bello on Biomarkers in Follicular Lymphoma

August 31st 2018

Celeste Bello, MD, hematologist/oncologist, Moffitt Cancer Center, discusses investigational biomarkers in follicular lymphoma.

Dr. Ascierto on Triplet Therapy in BRAF+ Melanoma

August 31st 2018

Paolo A. Ascierto, MD, director of the Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy at the National Tumor Institute Fondazione G. Pascale in Naples, discusses investigational triplet therapies in patients with BRAF-positive melanoma.

Dr. Wirth on Takeaways From the SELECT Trial in Thyroid Cancer

August 31st 2018

Lori J. Wirth, MD, associate professor of medicine, Harvard Medical School, medical director, Center for Head and Neck Cancers, Massachusetts General Hospital, discusses takeaways from the SELECT trial in patients with thyroid cancer.